The LSG Viral Inactivation Buffer Inactivir®, developed in collaboration with the University of Bedfordshire, has been formulated to provide a buffer that will inactivate viruses such as Covid-19, seasonal influenza, SARS, MERS and Ebola.
The use of samples collected in Inactivir® will increase laboratory throughput by reducing the requirement for Category 2+/3 handling of potentially pathogenic samples, increasing the speed and ease of testing. This formulation has been validated by Public Health England.
Any viral particles within the patients samples contained within the tube are inactivated and rendered non-pathogenic.
Samples do not need to be maintained at +4°C, removing the need for a cold chain in handling.
The buffer components are widely compatible with current RNA extraction protocols and can be used without disruption to current processing protocols.
The buffer acts as a stabiliser since the formulation will destroy the enzymes and proteins (including RNAses) which are responsible for the degradation of the RNA/DNA.
Life Science Production (LSP) is a Division of Life Science Group Ltd (LSG). LSP is a privately owned UK company providing a range of quality foetal bovine serum, Human AB serum, other cell culture sera, media and reagents together with Custom Manufacturing services of serum, buffers, and media.